川宁生物(301301) - 2024 Q1 - 季度财报

Revenue and Profit Growth - Revenue for the first quarter of 2024 increased by 19.96% to 1,523,218,164.00 yuan compared to the same period last year[4] - Net profit attributable to shareholders of the listed company surged by 100.98% to 352,614,874.42 yuan year-over-year[4] - Total revenue for Q1 2024 reached 1,523,218,164.00 RMB, a 19.98% increase compared to 1,269,733,317.68 RMB in the same period last year[21] - Net profit attributable to the parent company's owners was 352,614,874.42 RMB, a 101.03% increase from 175,446,682.72 RMB in Q1 2023[22] - Operating profit surged by 98.48% to 423,227,499.00 RMB from 213,237,446.52 RMB in the same period last year[22] Cash Flow and Financial Position - Operating cash flow improved significantly by 699.12% to 270,569,372.13 yuan from a negative figure in the previous year[4] - Cash and cash equivalents increased by 120.83% to 125,108,854.97 yuan, driven by reduced debt repayments and increased collections[11] - Net cash flow from operating activities was 270,569,372.13 yuan, a substantial improvement from -45,161,408.27 yuan in the previous period[25] - Net cash flow from investing activities was -79,956,654.60 yuan, compared to -4,830,726.92 yuan in the previous period[26] - Net cash flow from financing activities was -66,575,155.57 yuan, an improvement from -550,367,881.27 yuan in the previous period[26] - The net increase in cash and cash equivalents was 125,108,854.97 yuan, compared to -600,590,344.17 yuan in the previous period[26] - The ending balance of cash and cash equivalents was 883,122,418.32 yuan, up from 758,013,563.35 yuan at the beginning of the period[26] Asset and Liability Changes - Total assets grew by 4.29% to 10,573,868,624.95 yuan compared to the end of the previous year[4] - Equity attributable to shareholders of the listed company increased by 5.17% to 7,320,330,771.43 yuan[4] - Total liabilities increased by 2.38% to 3,240,654,896.23 RMB compared to the beginning of the year[19] - Long-term borrowing rose by 35.17% to 482,999,999.99 RMB from 357,333,333.00 RMB at the start of the year[19] - Total assets grew by 4.29% to 10,573,868,624.95 RMB compared to the beginning of the year[20] - Retained earnings increased by 26.85% to 1,666,350,780.61 RMB from 1,313,735,906.19 RMB at the start of the year[20] Accounts Receivable and Prepayments - Accounts receivable financing rose by 69.90% to 1,113,523,155.86 yuan due to increased sales and collections[8] - Prepayments surged by 191.84% to 131,042,579.66 yuan, mainly due to increased prepayments for planting and land rent[8] - Contract liabilities increased by 91.28% to 55,362,293.43 yuan, reflecting higher advance payments from customers[9] Financial Expenses and R&D - Financial expenses decreased by 47.17% to 12,667,068.96 yuan due to reduced interest payments[10] - Financial expenses decreased by 47.17% to 12,667,068.96 RMB compared to 23,979,158.76 RMB in Q1 2023[21] - R&D expenses increased by 21.11% to 16,682,182.70 RMB compared to 13,774,801.25 RMB in Q1 2023[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 31,616[12] - Sichuan Kelun Pharmaceutical Co., Ltd. holds 70.63% of the shares, totaling 1,569,887,643 shares[12] - Shanghai Dongjun Asset Management Co., Ltd. holds 4.35% of the shares, totaling 96,629,213 shares[12] - Chengdu Kelun Ninghe Enterprise Management Partnership holds 3.20% of the shares, totaling 71,080,300 shares[12] - Chengdu Kelun Ningbei Enterprise Management Partnership holds 2.36% of the shares, totaling 52,563,132 shares[13] - Shouguang Yixing Investment Partnership holds 2.10% of the shares, totaling 46,674,316 shares[13] - Shouguang Huining Chiyuan Investment Partnership holds 1.80% of the shares, totaling 40,000,000 shares[13] - Hong Kong Securities Clearing Company holds 0.67% of the shares, totaling 14,820,426 shares[13] - Shouguang Yihong Jutou Investment Partnership holds 0.60% of the shares, totaling 13,309,400 shares[13] - Shouguang Zhongju Ningcheng Investment Partnership holds 0.58% of the shares, totaling 12,909,913 shares[13] Earnings Per Share - Basic earnings per share (EPS) for Q1 2024 was 0.16 RMB, doubling from 0.08 RMB in the same period last year[23] Cash Flow from Operations - Sales of goods and services received cash of 789,257,631.96 yuan, a significant increase from 497,255,911.49 yuan in the previous period[25] - Cash paid for the purchase of goods and services decreased to 290,119,712.18 yuan from 321,377,284.21 yuan in the previous period[25] - Cash paid for employee compensation increased to 147,584,652.70 yuan from 119,280,108.62 yuan in the previous period[25] - Cash received from borrowings was 150,000,000.00 yuan, a significant increase from 1,800,000.00 yuan in the previous period[26]